IOA-237
/ iOnctura
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 11, 2021
[VIRTUAL] IOA-237 - A potent anti-CD73 mAb demonstrates monotherapeutic and combination efficacy in solid tumor models
(AACR 2021)
- "Best-in-class potential was confirmed with head-to-head comparison against a clinical stage anti-CD73 mAb, MEDI9447. These data indicate the potential of IOA-237 in monotherapeutic and combination therapeutic approaches and warrants further development. Additional in vitro and in vivo efficacy studies are ongoing and non-clinical safety studies are being planned."
Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • NT5E
1 to 1
Of
1
Go to page
1